No headlines found.
Business Wire (Thu, 9-Apr 4:05 PM ET)
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
Business Wire (Tue, 7-Apr 9:15 AM ET)
Business Wire (Wed, 18-Mar 8:00 AM ET)
Business Wire (Thu, 5-Mar 4:01 PM ET)
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
Business Wire (Fri, 20-Feb 8:00 AM ET)
TriSalus Life Sciences Proposes Public Offering
Business Wire (Thu, 19-Feb 4:01 PM ET)
Business Wire (Mon, 9-Feb 9:00 AM ET)
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Trisalus Life Sciences trades on the NASDAQ stock market under the symbol TLSI.
As of April 27, 2026, TLSI stock price declined to $4.50 with 116,732 million shares trading.
TLSI has a beta of 1.21, meaning it tends to be more sensitive to market movements. TLSI has a correlation of 0.07 to the broad based SPY ETF.
TLSI has a market cap of $275.88 million. This is considered a Small Cap stock.
Last quarter Trisalus Life Sciences reported $13 million in Revenue and -$.21 earnings per share. This beat revenue expectation by $185,000 and missed earnings estimates by -$.08.
The top ETF exchange traded funds that TLSI belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
TLSI has underperformed the market in the last year with a return of -20.4%, while the SPY ETF gained +32.2%. In the last 3 month period, TLSI fell short of the market, returning -17.3%, while SPY returned +4.0%. However, in the most recent 2 weeks TLSI has outperformed the stock market by returning +6.6%, while SPY returned +5.3%.
TLSI support price is $4.43 and resistance is $4.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLSI shares will trade within this expected range on the day.
